Lateral pelvic lymph nodes for rectal cancer: A review of diagnosis and management

Table 2 Variables in treatment of lateral pelvic lymph node dissection in recent meta-analyses and systematic reviews

Ref.	Study (RCT)	Treatment	Patients	CRT or RT	OS	DFS	TR	LR	LLR
Gao et al[63], 2020	12 (6)	TME + LPLD	1952	359	5-yr HR 0.93, 95%CI: 0.71-1.22, P = 0.62	5-yr HR 0.99, 95%CI: 0.74-1.34, P = 0.96	5-yr RR 0.98, 95%CI: 0.81-1.18, P = 0.83	5-yr RR 0.71, 95%CI: 0.56-0.89, P = 0.003	5-yr RR 0.49, 95%CI: 0.18-1.28, P = 0.14
		TME	2506	1009
Wang et al[64], 2020	16 (4)	TME + LPLD	2984		HR 1.11, 95%CI: 0.77-1.61, P = 0.57	HR 1.05, 95%CI: 0.85-1.30, P = 0.64		OR 0.93, 95%CI: 0.56-1.54, P = 0.78
		TME	3397
Ma et al[65], 2020	26 (5)	TME + LPLD	3171	417	5-yr HR 1.14, 95%CI: 0.85-1.54	5-yr HR 1.07, 95%CI: 0.89-1.28, P = 0.496	OR 1.00, 95%CI: 0.80-1.24	OR 0.90, 95%CI: 0.76-1.06, P = 0.208
		TME	3694	1102
Emile et al[66], 2020	29 (5)	TME + LPLD	4194	551	HR 1.056, 95%CI: 0.98-1.13, P = 0.13	HR 1.02, 95%CI: 0.97-1.07, P = 0.37		HR 0.96, 95%CI: 0.75-1.25, P = 0.79
		TME	6452	1467
Hajibandeh et al[67], 2020	18 (2)	TME + LPLD	2762	321	5-yr OR 1.01, 95%CI: 0.78-1.30, P = 0.94	5-yr OR 1.07, 95%CI: 0.86-1.32, P = 0.54
		TME	3371	735			OR 0.97, 95%CI: 0.72-1.29, P = 0.82	OR 1.01, 95%CI: 0.72-1.42, P = 0.97
Law et al[68], 2020	6 (0)	CRT + TME + LPLD	268	268		5-yr OR 0.70, 95%CI: 0.20-2.39, P = 0.57		5-yr OR 0.42, 95%CI: 0.14-1.24, P = 0.12
		CRT + TME	1210	1210
Yang et al[69], 2020	8 (1)	CRT + TME + LPLD	435	435
		CRT + TME	1461	1461	HR 0.78, 95%CI: 0.32-1.88, P = 0.58	HR 0.94, 95%CI: 0.62-1.43, P = 0.77		OR 0.82, 95%CI: 0.27-2.46, P = 0.72	OR 2.99, 95%CI: 1.20-7.44, P = 0.02

CI: Confidence interval; CRT: Chemoradiation therapy; DFS: Disease-free survival; HR: Hazard ratio; LLR: Local lateral recurrence; LPLD: Lateral pelvic lymph node dissection; LR: Local recurrence; OR: Odds ratio; OS: Overall survival; RCT: Randomized controlled trial; RR: Risk ratio; RT: Radiation therapy; TME: Total mesorectal excision; TR: Total recurrence.